What is the primary business of Resverlogix?

Resverlogix's primary business is the research and development novel biopharmaceuticals for the treatment of unmet medical markets. The company's principle areas of research are cardiovascular disease, cancer, and fibrotic disease.

What symbol does Resverlogix trade under?

Resverlogix Corp. trades on the Toronto Stock Exchange under the symbol RVX.

Where is the company located?

Resverlogix is based in Calgary, Alberta, Canada, where it operates the city's largest off-campus research laboratory.

What does 'Resverlogix' mean?

Dr. Wong’s early research was based on the cardioprotective effects of compounds found in red wine, including Resveratrol, hence the namesake of the company. Our current research has moved past these naturally occurring compounds, and involves proprietary novel small molecules that are more ‘drug-like’.

Cardiovascular Disease FAQ

What is cardiovascular disease?

Cardiovascular disease (CVD) is a broad group of diseases of the heart and blood vessels. The most common cardiovascular diseases arise from the progression of atherosclerosis. The process of atherosclerosis leads to narrowing of the blood vessel lumen and in severe cases leads to complete blockage leading to heart attack and stroke. Over the past few decades it has been established that the risk of CVD can be reduced by enhancing levels of ApoA-I - the key cardioprotective protein of HDL, the “Good” cholesterol.

How is high cholesterol currently treated?

Current treatments for high cholesterol primarily focus on the reduction of low-density lipoprotein (LDL), the "Bad" Cholesterol. While many widely prescribed LDL treatments such as statins effectively slow the buildup of dangerous atherosclerotic plaque, they do little to reduce pre-existing plaque. Statin drugs also have a broad spectrum of potential side effects including severe liver toxicity.

What is high-density lipoprotein?

High-Density Lipoprotein (HDL) is commonly known as "Good" Cholesterol. In a process termed reverse cholesterol transport (RCT), HDL carries cholesterol from the arteries to the liver where it is catabolized and eliminated from the body. The net effect of increasing HDL is an increase in RCT that leads to lower total body cholesterol and a reduced risk of cardiovascular disease. For this reason, HDL is known as "Good" cholesterol.

What is Apolipoprotein A-I (ApoA-I)?

Apolipoprotein A-I (ApoA-I) comprises 70% of the total protein content of HDL. Several studies show a direct relationship between increased ApoA-I and an increase in HDL in the body. Exciting research published in the Journal of the American Medical Association in 2003 showed an injection of a variant of ApoA-I could dramatically reduce pre-existing atherosclerotic plaque.

How do NexVas™ PR small molecules increase ApoA-I?

Resverlogix's molecules increase the transcription of ApoA-I. This can potentially lead to an innovative method of reducing atherosclerotic plaque.

When will NexVas™ PR small molecules be available to patients?

Like other experimental drugs, NexVas™ PR will not be available to the public until its safety and efficacy has been tested in rigorous clinical trials and approved for use by regulatory bodies such as Health Canada and the U.S. Food & Drug Administration (FDA). Resverlogix will begin its first administration in man studies in the first quarter of 2007, with a potential Phase I trial expected to follow later in the same year.

Cancer FAQ

Why is Cancer hard to treat?

Cancer results from inappropriate expression of genes that control cellular proliferation, thus causing previously normal cells to grow in an unchecked fashion. Because cancer cells are derived, at least initially, from normal body tissues, they are difficult for the body to differentiate from normal cells. This reduces the ability of the immune system to eliminate the abnormal cells and leads to the need for medical intervention.

What is TGF-β Shield™?

A growing cancer often manages to evade host defenses by actively suppressing the immune system's cancer-killing activities, sometimes through the increase of transforming growth factor beta, TGF-β. A protein has been demonstrated by Resverlogix to inhibit the ability of TGF-β to incapacitate the immune system. The Company has demonstrated that delivery of this protein specifically to key immune system cells (lymphocytes) increases the body's inherent ability to kill cancer cells.

Media

Where can I find news and press releases about Resverlogix?

To view a listing of Resverlogix's press releases, click here.

How do I get photos or videos from you to use in my story?

Please email Corporate Communications and let us know what the photo or video will be used for, any specifications and your deadline.

How do I request an interview with a Resverlogix executive?

Please email Corporate Communications and let us know which Resverlogix executive you would like to interview, the nature of the interview, your contact information and your deadline.

How do I invite a Resverlogix executive to speak at my event?

Please email Corporate Communications and let us know which Resverlogix executive you would like to speak at your event, the nature of the event, your contact information and the date of the event.

Request to be Contacted

If we have not been able to answer your question, please click here to fill out a request form and we will get back to you.